Zymeworks Inc. (NASDAQ: ZYME) is 9.80% higher on its value in year-to-date trading and has touched a low of $4.11 and a high of $10.80 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ZYME stock was last observed hovering at around $8.47 in the last trading session, with the day’s gains setting it 0.16% off its average median price target of $13.00 for the next 12 months. It is also 53.35% off the consensus price target high of $18.50 offered by analysts, but current levels are -7.88% lower than the price target low of $8.00 for the same period.
Currently trading at $8.63, the stock is 3.56% and -1.58% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.58 million and changing 1.89% at the moment leaves the stock 22.47% off its SMA200. ZYME registered 43.83% gain for a year compared to 6-month gain of 72.60%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The stock witnessed a -3.25% loss in the last 1 month and extending the period to 3 months gives it a 43.83%, and is 7.88% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.03% over the week and 5.57% over the month.
Zymeworks Inc. (ZYME) has around 291 employees, a market worth around $554.05M and $412.50M in sales. Current P/E ratio is 4.91. Profit margin for the company is 30.10%. Distance from 52-week low is 109.98% and -20.09% from its 52-week high. The company has generated returns on investments over the last 12 months (24.30%).
Zymeworks Inc. (ZYME) Analyst Forecasts
The EPS is expected to grow by 146.40% this year
Zymeworks Inc. (ZYME) Top Institutional Holders
The shares outstanding are 66.53M, and float is at 52.02M with Short Float at 13.58%.
Zymeworks Inc. (ZYME) Insider Activity
A total of 19 insider transactions have happened at Zymeworks Inc. (ZYME) in the last six months, with sales accounting for 5 and purchases happening 14 times. The most recent transaction is an insider sale by Klompas Neil A, the company’s President & COO. SEC filings show that Klompas Neil A sold 2,977 shares of the company’s common stock on Mar 10 at a price of $7.83 per share for a total of $23298.0. Following the sale, the insider now owns 17032.0 shares.
Zymeworks Inc. disclosed in a document filed with the SEC on Jan 20 that EcoR1 Capital, LLC (10% Owner) bought a total of 163,400 shares of the company’s common stock. The trade occurred on Jan 20 and was made at $9.88 per share for $1.62 million. Following the transaction, the insider now directly holds 9.89 million shares of the ZYME stock.
Still, SEC filings show that on Jan 19, EcoR1 Capital, LLC (10% Owner) acquired 144,100 shares at an average price of $9.49 for $1.37 million. The insider now directly holds 9,724,073 shares of Zymeworks Inc. (ZYME).
Zymeworks Inc. (ZYME): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -10.10% down over the past 12 months and Pfizer Inc. (PFE) that is -22.91% lower over the same period.